Valicenti Advisory Services Inc. Has $5.09 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Valicenti Advisory Services Inc. lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,786 shares of the medical research company’s stock after selling 357 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.3% of Valicenti Advisory Services Inc.’s holdings, making the stock its 25th largest position. Valicenti Advisory Services Inc.’s holdings in Thermo Fisher Scientific were worth $5,091,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. IFG Advisors LLC raised its position in shares of Thermo Fisher Scientific by 3.3% in the third quarter. IFG Advisors LLC now owns 532 shares of the medical research company’s stock valued at $329,000 after purchasing an additional 17 shares during the period. Stonegate Investment Group LLC raised its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company’s stock worth $3,531,000 after acquiring an additional 18 shares during the period. Trivant Custom Portfolio Group LLC boosted its holdings in Thermo Fisher Scientific by 0.4% during the third quarter. Trivant Custom Portfolio Group LLC now owns 4,398 shares of the medical research company’s stock valued at $2,720,000 after acquiring an additional 19 shares during the period. Axiom Advisory LLC grew its position in shares of Thermo Fisher Scientific by 1.6% in the third quarter. Axiom Advisory LLC now owns 1,216 shares of the medical research company’s stock valued at $720,000 after purchasing an additional 19 shares during the last quarter. Finally, Angeles Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Angeles Wealth Management LLC now owns 3,921 shares of the medical research company’s stock worth $2,425,000 after purchasing an additional 19 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on TMO. Evercore ISI dropped their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Bernstein Bank boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Bank of America decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Finally, Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $648.95.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,850 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,611,804.88. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 34,850 shares of company stock worth $19,123,197. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $571.80 on Wednesday. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a 50 day moving average of $536.74 and a 200-day moving average of $570.35. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $218.72 billion, a price-to-earnings ratio of 35.83, a PEG ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific announced that its board has approved a stock buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.